<DOC>
	<DOCNO>NCT03028350</DOCNO>
	<brief_summary>The purpose phase 2 study ass safety efficacy oral ifetroban treatment aspirin-exacerbated respiratory disease ( AERD ) . AERD disease involve asthma , recur nasal polyp , respiratory reaction aspirin nonsteroidal anti-inflammatory drug .</brief_summary>
	<brief_title>Oral Ifetroban Treat Aspirin Exacerbated Respiratory Disease ( AERD )</brief_title>
	<detailed_description>This randomize , placebo-controlled , double-blind phase 2 trial evaluate approximately 76 subject symptomatic AERD safety efficacy 8 week oral ifetroban treatment . Eligible AERD subject randomize receive 8 week either oral ifetroban daily match placebo follow 2-week post-treatment period .</detailed_description>
	<mesh_term>Respiration Disorders</mesh_term>
	<mesh_term>Respiratory Tract Diseases</mesh_term>
	<mesh_term>Asthma , Aspirin-Induced</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Ifetroban</mesh_term>
	<criteria>1 . History physiciandiagnosed asthma 2 . History nasal polyposis 3 . History least two reaction oral aspirin nonselective cyclooxygenase inhibitor feature low airway involvement ( cough , chest tightness , wheeze , dyspnea ) , diagnosis AERD physicianconducted challenge aspirin last five year start treatment . 4 . Stable asthma ( postbronchodilator FEV1 ≥ 60 % , glucocorticoid burst least two week prior start treatment , hospitalization emergency room visit asthma least three month prior start treatment dose &gt; 1000 µg fluticasone equivalent daily ) . 5 . ≥ 18 year age 6 . Exhibit symptomatic AERD within two week start treatment demonstrate score least 20 Sinonasal Outcome Test ( SNOT ) 22 . 1 . Current smoking , define daily tobacco smoking last six month least one instance tobacco smoking last three month . 2 . Current pregnancy breastfeed 3 . Use oral systemic steroid ( e.g . prednisone equivalent ) &gt; 20 mg daily last four week start treatment . 4 . Daily use longacting antihistamine , 5lipoxygenase inhibitor ( e.g . zileuton ) leukotriene receptor antagonist ( e.g . montelukast ) last two week start treatment . 5 . Less 12 month allergy shot ( maintenance dose allergy shot allow treatment duration exceed 12 month ) . 6 . Any use nonsteroidal antiinflammatory drug ( NSAIDs ) drug inhibits cyclooxygenase enzyme last two week start treatment . 7 . History bleed diathesis use anticoagulant antiplatelet drug last two week start treatment . 8 . Any immunosuppressive treatment include limited methotrexate , cyclosporine , mycophenolate , tacrolimus , gold , penicillamine , sulfasalazine , hydroxychloroquine , azathioprine , cyclophosphamide , immunotherapy last two week start treatment ( maintenance dose allergy shot allow treatment duration exceed 12 month ) . 9 . Endoscopic sinus surgery / polypectomy within past three month 10 . Previously treat clinical trial ifetroban within past three month . 11 . Previously treat investigational drug within eight week five halflives , whichever longer , screen 12 . Conditions/concomitant disease make unevaluable efficacy endpoint</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>